Startups
Learn about YESCARTA® (axicabtagene ciloleucel) a CAR T-cell therapy for certain types of non-Hodgkin lymphoma in adults. See Important Safety Information & Warnings.
Overview
Location
United States
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 19, 2019 | “Squeezing” Cells Could Transform Cell Therapy Manufacturing | Manufacturing today’s cell therapies remains expensive and complex due to the need for viruses or electric shocks to engineer patient cells. Yescarta®, for example, one of the first CAR-T therapies approved for sale, takes 3-4 weeks to reac... |
| Aug 22, 2019 | Стартап Cell Vault предлагает услугу заморозки иммунных клеток — их модификация может вылечить множество видов рака Статьи редакции | Компания привлекла $1 млн инвестиций и назвала себя «первым в мире банком иммунных клеток». Врачи сомневаются в способности замороженных клеток помочь людям и подозревают стартап в обмане. 5 5 комментариев 1741 просмотров Cell Vault заявляе... |
| Oct 9, 2018 | CAR-T therapies face logistical bottleneck as market set to see major growth | The only two CAR-Ts currently approved are Novartis’ Kymriah (tisagenlecleucel), for aggressive forms of pediatric leukemia and adult lymphoma, and Gilead Sciences’ Yescarta (axicabtagene ciloleucel), for the lymphoma indication alone. The ... |
| Oct 8, 2018 | Novartis CAR-T likely improves long-term survival and is cost-effective, study finds | Additionally, Kymriah, whose list price is $475,000, was shown to have a cost per quality-adjusted life year, or cost per QALY, of $46,000, in comparison with clofarabine chemotherapy. Across scenario analyses, the cost per QALY ranged from... |
| Novartis CAR-T likely improves long-term survival and is cost-effective, study finds | Novartis’ CAR-T therapy for acute lymphoblastic leukemia in pediatric patients appears to significantly increase survival while exerting costs to the healthcare system that are in line with its benefits, a new study has found. The study, pu... | |
| CAR-T therapies face logistical bottleneck as market set to see major growth | Amid all the excitement around CAR-T cell therapies, some experts are concerned that a coming wave of new products on the market may overwhelm the medical centers that administer them. Because of this, they said, manufacturers need to strea... |
Reviews 0
FAQ about Yescarta
What has the press written about Yescarta?
Parsers VC has collected 7 articles mentioning Yescarta, among them ““Squeezing” Cells Could Transform Cell Therapy Manufacturing” (Nov 19, 2019) and “Стартап Cell Vault предлагает услугу заморозки иммунных клеток — их модификация может вылечить множество видов рака Статьи редакции” (Aug 22, 2019).
Is Yescarta still active?
Yes, Yescarta is active; its latest activity on Parsers VC dates from Jan 17, 2020.